103 related articles for article (PubMed ID: 9253807)
21. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time.
Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
Haemostasis; 1996; 26(3):140-9. PubMed ID: 8738588
[TBL] [Abstract][Full Text] [Related]
22. Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis.
Kaiser B; Simon A; Markwardt F
Thromb Haemost; 1990 Feb; 63(1):44-7. PubMed ID: 2140204
[TBL] [Abstract][Full Text] [Related]
23. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
[TBL] [Abstract][Full Text] [Related]
24. Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty.
Meyer BJ; Fernández-Ortiz A; Mailhac A; Falk E; Badimon L; Michael AD; Chesebro JH; Fuster V; Badimon JJ
Circulation; 1994 Nov; 90(5):2474-80. PubMed ID: 7955205
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins.
Zhang B; Wieslander JB
Microsurgery; 1996; 17(2):89-96. PubMed ID: 8914063
[TBL] [Abstract][Full Text] [Related]
26. Treatment of an acute flush reaction caused by subcutaneous r-hirudin with pegylated hirudin.
Harenberg J; Hoffmann U; Huhle G; Song XH; Wang LC
Br J Haematol; 2000 Mar; 108(3):528-30. PubMed ID: 10759710
[TBL] [Abstract][Full Text] [Related]
27. Tissue plasminogen activator levels after single intracisternal injection in patients with subarachnoid hemorrhage.
Jito J; Nakasu Y; Nakasu S; Hatsuda N; Matsuda M
Neurol Med Chir (Tokyo); 2004 Feb; 44(2):55-60; discussion 60. PubMed ID: 15018324
[TBL] [Abstract][Full Text] [Related]
28. Anti-r-hirudin antibodies reveal clinical relevance through direct functional inactivation of r-hirudin or prolongation of r-hirudin's plasma halflife.
Huhle G; Liebe V; Hudek R; Heene DL
Thromb Haemost; 2001 May; 85(5):936-8. PubMed ID: 11372692
[No Abstract] [Full Text] [Related]
29. Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis.
Marsh Lyle E; Lewis SD; Lehman ED; Gardell SJ; Motzel SL; Lynch JJ
Thromb Haemost; 1998 Mar; 79(3):656-62. PubMed ID: 9531058
[TBL] [Abstract][Full Text] [Related]
30. Quantitative determination of PEG-hirudin in human plasma using a competitive enzyme-linked immunosorbent assay.
Song XH; Huhle G; Wang LC; Harenberg J
Thromb Res; 2000 Jul; 99(2):195-202. PubMed ID: 10946094
[TBL] [Abstract][Full Text] [Related]
31. A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection.
Zhao B; Zhang Y; Huang Y; Yu J; Li Y; Wang Q; Ma Y; Song HY; Yu M; Mo W
Thromb Haemost; 2017 Jan; 117(1):44-56. PubMed ID: 27904902
[TBL] [Abstract][Full Text] [Related]
32. Prevention of experimental coronary thrombosis by hirudin.
Bucha E; Nowak G; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):52-8. PubMed ID: 2459032
[TBL] [Abstract][Full Text] [Related]
33. Determination of the dosage of recombinant hirudin to inhibit arterial thrombosis in baboons.
Kotzé HF; Lamprecht S; Van Wyk V; Roodt JP; Badenhorst PN
J Pharm Sci; 2000 May; 89(5):579-85. PubMed ID: 10756323
[TBL] [Abstract][Full Text] [Related]
34. Arterial thrombin activity after angioplasty in an atherosclerotic rabbit model: time course and effect of hirudin.
Barry WL; Gimple LW; Humphries JE; Powers ER; McCoy KW; Sanders JM; Owens GK; Sarembock IJ
Circulation; 1996 Jul; 94(1):88-93. PubMed ID: 8964123
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model.
Montoney M; Gardell SJ; Marder VJ
Circulation; 1995 Mar; 91(5):1540-4. PubMed ID: 7867196
[TBL] [Abstract][Full Text] [Related]
36. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species: a comparison of mathematical models.
Godfrey KR; Tanswell P; Bates RA; Chappell MJ; Madden FN
Biopharm Drug Dispos; 1998 Mar; 19(2):131-40. PubMed ID: 9533114
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of heparin-resistant microarterial thrombosis by recombinant hirudin: a specific thrombin inhibitor.
Arnljots B; Bergqvist D
Plast Reconstr Surg; 1995 Apr; 95(5):894-900. PubMed ID: 7708874
[TBL] [Abstract][Full Text] [Related]
38. An ultrasound-responsive nano delivery system of tissue-type plasminogen activator for thrombolytic therapy.
Uesugi Y; Kawata H; Jo J; Saito Y; Tabata Y
J Control Release; 2010 Oct; 147(2):269-77. PubMed ID: 20696194
[TBL] [Abstract][Full Text] [Related]
39. Early plus delayed hirudin reduces restenosis in the atherosclerotic rabbit more than early administration alone: potential implications for dosing of antithrombin agents.
Thome LM; Gimple LW; Bachhuber BG; McNamara CA; Ragosta M; Gertz SD; Powers ER; Owens GK; Humphries JE; Sarembock IJ
Circulation; 1998 Nov; 98(21):2301-6. PubMed ID: 9826318
[TBL] [Abstract][Full Text] [Related]
40. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
Lucore CL; Fujii S; Sobel BE
Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
